Puma Biotechnology licenses with CANbridge to commercialize NERLYNX in China

Biopharmaceutical company focused on developing Western drug candidates in China and North Asia, CANbridge Life Sciences undertakes licensing agreement to develop and commercialize NERLYNX in China, Taiwan, Hong Kong and Macao from Puma Biotechnology.

James Xue, PhD, MBA, CANbridge Life Sciences Chairman, CEO and President stated “By addressing a significant unmet medical need for the extended adjuvant treatment of patients with early-stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy, we believe that NERLYNX will transform the lives of patients. We are honored to have been selected by Puma to develop and commercialize this important therapy, which we believe has significant commercial potential in greater China in HER2-positive cancers, including gastric cancer, where CANbridge will be leading the development in greater China. This transformative collaboration is an important demonstration of our capabilities as a leading biopharmaceutical company and partner-of-choice in the greater China region. We will work closely with Puma Biotechnology  and regulatory authorities toward earliest market approval of NERLYNX.”

Neratinib was approved by the U.S. Food and Drug Administration (FDA) in July 2017 for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets.